Text Size
- News Releases
- What's New
- 01 Jun
- Chugai Selected as “DX Platinum Companies 2023-2025” in Digital Transformation Stocks (DX Stocks) 2023
- 30 May
- Personnel Changes
- 30 May
- New Investment of Over 50 Billion Yen in Bio Manufacturing Facilities to Strengthen the Production Base to Support the Rapid Launch of In-House Projects
- 26 May
- Chugai Obtains Approval for FoundationOne Liquid CDx Cancer Genomic Profile to Be Used as a Companion Diagnostic for Novartis’ MET Inhibitor, Capmatinib, Which Is Approved for MET Exon 14 Skipping Mutation-Positive Advanced and/or Recurrent Unresectable Non-Small Cell Lung Cancer
- Share this site
